rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PGEN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Precigen: Upgrading To Buy As Competitive Fears Over VOCERYQ Look Overblown
      Nov 18Seeking AlphaPGEN
      Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule

      GERMANTOWN, MD/ ACCESS Newswire/ November 10, 2026/ Precigen Inc. reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS ®, as the company achieved positive cash flow a quarter ahead of schedule and posted its second consecutive profitable period. The company's third-quarter...

      Nov 10NasdaqPGEN
      Hunting for the Next Biopharma Stock to Surge 700%

      Precigen has the same combination that made Xeris work: a fast-growing product and a pipeline the market isn’t pricing in.

      Nov 9TheStreetPGENXERS
      What Makes Precigen (PGEN) a New Buy Stock
      Nov 9Yahoo FinancePGEN
      Precigen (PGEN) Stock Looks Fully Priced On Current Earnings
      Nov 6Yahoo FinancePGEN
      Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
      Nov 5Yahoo FinancePGEN
      Citizens raises Precigen stock price target to $12 on strong sales
      Nov 5Investing.comPGEN
      Precigen Inc (PGEN) Q3 2026 Earnings Call Highlights: Triple-Digit Revenue Surge, First ...

      Precigen Inc (PGEN) posts $72.9 million in Q3 net product revenue, achieves back-to-back profitability, and lays out its playbook to fend off a newly approved rival in RRP.

      Nov 5Yahoo FinancePGEN
      What Precigen (PGEN) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinancePGEN
      Precigen earnings beat by $0.03, revenue topped estimates
      Nov 5Investing.comPGEN
      Precigen Q3 2026 Earnings Call Transcript
      Nov 4BenzingaPGEN
      Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
      Nov 4Yahoo FinancePGEN
      Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
      Nov 4MorningstarPGEN
      Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages
      Nov 4Seeking AlphaINOPGEN
      All eyes on Precigen earnings after rival wins FDA approval
      Nov 4Investing.comPGEN
      Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos?
      Nov 3Yahoo FinanceINOPGEN
      Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
      Nov 2Yahoo FinancePGEN
      PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings
      Nov 2Yahoo FinanceINOPGEN
      Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4

      Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.

      Oct 28Yahoo FinancePGEN
      Precigen (PGEN) Stock May Be Fully Priced On Its Huge 3 Year Run

      Precigen has delivered a very large share price gain over the past few years, which naturally raises a sharper question for you as an investor. Is the current US$6.66 price adequately supported by the sales the business is generating today and what the market expects it to produce next? Over the past 3 years, Precigen has produced a very large share price return, so a lot of optimism about its commercial potential is already embedded in the debate around its sales base. The group’s future...

      Oct 20Yahoo FinancePGEN
      Precigen (PGEN): Commercial Launch Success Validates Early Capital Raise Thesis
      Oct 12Yahoo FinancePGEN
      PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

      Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

      Oct 5Yahoo FinancePGEN
      The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies

      Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.

      Oct 5Yahoo FinanceCORTPGENABTBHC
      Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

      Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

      Oct 1Yahoo FinancePGEN
      Precigen: FDA’s Platform Technology Designation And Institutional Crossover Effect (PGEN)

      Precigen's PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP. Read why PGEN stock is a strong buy.

      Sep 30Seeking AlphaPGEN
      PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

      Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

      Sep 30Yahoo FinancePGEN
      Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

      Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]

      Sep 29Yahoo FinancePGEN
      Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

      Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...

      Sep 26Yahoo FinancePGEN
      MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

      Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

      Sep 25Yahoo FinancePGEN
      Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

      Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...

      Sep 25Yahoo FinancePGEN
      Precigen stock hits 52-week high at 8.05 USD
      Sep 25Investing.comPGEN
      B.Riley initiates Precigen stock coverage with buy on drug launch
      Sep 25Investing.comPGENRILYRILYGRILYLRILYNRILYTRILYZ
      Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

      Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

      Sep 24Yahoo FinancePGEN
      FDA grants platform technology status to Precigen’s AdenoVerse
      Sep 21Investing.comPGEN
      Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

      Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®. The designation reflects the adaptability and potential of the platform to address a broad ran

      Sep 21Yahoo FinancePGEN
      Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base

      Precigen has seen its stock climb sharply in recent years, which naturally puts the focus on what investors are paying for each dollar of its sales. With the share price at US$7.87 at the last close, the open question is whether that level is adequately supported by the company’s current revenue base. Over the past 3 years the stock has returned about 4.6x, which puts a lot of weight on whether its sales profile can carry that kind of re-rating. For a business like Precigen, future outcomes...

      Sep 18Yahoo FinancePGEN
      Precigen stock hits 52-week high at 7.74 USD
      Sep 17Investing.comPGEN
      Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

      PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

      Sep 14Yahoo FinancePGEN
      Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

      Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

      Sep 10Yahoo FinancePGEN
      Precigen Insider Sold Shares Worth $1,376,400, According to a Recent SEC Filing

      Jeffrey B Kindler, Director, on August 26, 2026, sold 185,000 shares in Precigen (PGEN) for $1,376,4

      Aug 31Yahoo FinancePGEN
      Precigen director Jeffrey Kindler sells $1.38m in stock
      Aug 29Investing.comPGEN
      Precigen (PGEN) Draws Attention To Papzimeos, Is The Valuation Upside Already Priced In?

      Event driven interest in Precigen stock Fresh attention on Precigen (PGEN) follows commentary that new drug approvals and pipeline progress could support the Zacks Biomedical and Genetics industry, with Papzimeos highlighted for recurrent respiratory papillomatosis. Investors are weighing how Papzimeos commercial performance and Precigen's broader gene and cell therapy pipeline might relate to recent share price moves and the company’s current valuation profile. At a latest share price of...

      Aug 28Yahoo FinancePGEN
      Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy?

      Recent commentary on the Zacks Biomedical and Genetics industry highlighted Precigen’s past momentum, citing steady commercial performance from its sole marketed drug Papzimeos for recurrent respiratory papillomatosis and encouraging pipeline progress despite a challenging macro backdrop. The focus on Papzimeos as a single commercial pillar underscores both the company’s concentration risk and the importance of its broader development portfolio to diversify future revenue sources. We’ll now...

      Aug 28Yahoo FinancePGEN
      Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

      Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

      Aug 27Yahoo FinanceARQTHALOIOVAPGENRGEN
      Precigen director Nancy H. Agee buys $24,661 of PGEN stock
      Aug 26Investing.comPGEN
      Precigen CCO Phil Tennant sells $593,745 in stock
      Aug 25Investing.comPGENTNC
      Precigen COO Rutul Shah sells $375,000 in shares
      Aug 25Investing.comPGEN
      Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

      GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.

      Aug 25Yahoo FinancePGEN

      This is the newest page. Registered accounts read further back.